表紙:再生不良性貧血の世界市場:2020年~2027年
市場調査レポート
商品コード
994960

再生不良性貧血の世界市場:2020年~2027年

Global Aplastic Anemia Market, Size, Share, Opportunities and Forecast, 2020-2027

出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.87円
再生不良性貧血の世界市場:2020年~2027年
出版日: 2021年04月03日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

再生不良性貧血市場の成長を促進する主な要因は、世界中の造血系疾患の症例数の増加と、がん患者数の増加です。さらに、再生不良性貧血に対する技術的進歩と製薬部門における研究開発活動の成長が、市場成長の有利な機会を生み出しています。

当レポートでは、世界の再生不良性貧血市場について調査分析し、業界分析、セグメント別の市場分析、競合情勢、主要企業などについて、体系的な情報を提供しています。

目次

第1章 再生不良性貧血市場の調査手法と調査範囲

第2章 再生不良性貧血市場:市場定義と市場概要

第3章 再生不良性貧血市場:エグゼクティブサマリー

第4章 再生不良性貧血市場:市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 影響分析

第5章 世界の再生不良性貧血市場:業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • バリューチェーン分析
  • PEST分析
  • 価格分析
  • 規制分析
  • 償還分析
  • アンメットニーズ
  • 特許動向

第6章 世界の再生不良性貧血市場:COVID-19分析

  • 市場に対するCOVID-19の分析
  • COVID-19における価格動向
  • 需給スペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界の再生不良性貧血市場:治療タイプ別

  • イントロダクション
  • 治療タイプセグメント別の市場規模分析・前年比成長率分析
  • 治療タイプセグメント別の市場魅力指数
    • 輸血
    • 薬物治療
    • 骨髄移植

第8章 世界の再生不良性貧血市場:疾患タイプ別

  • イントロダクション
  • 疾患タイプセグメント別の市場規模分析・前年比成長率分析
  • 疾患タイプセグメント別の市場魅力指数
    • 後天性再生不良性貧血
    • 遺伝性骨髄不全症候群

第9章 世界の再生不良性貧血市場:投与経路別

  • イントロダクション
  • 投与経路セグメント別の市場規模分析・前年比成長率分析
  • 投与経路セグメント別の市場魅力指数
    • 静脈内
    • 経口

第10章 世界の再生不良性貧血市場:流通チャネル別

  • イントロダクション
  • 流通チャネルセグメント別の市場規模分析・前年比成長率分析
  • 流通チャネルセグメント別の市場魅力指数
    • 小売薬局
    • 病院薬局
    • オンライン薬局

第11章 世界の再生不良性貧血市場:地域別

  • イントロダクション
  • 地域別の市場規模分析・前年比成長率分析
  • 地域別の市場魅力指数
  • 北米
  • 欧州
  • 南米
  • アジア太平洋地域
  • 中東・アフリカ

第12章 世界の再生不良性貧血市場:競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第13章 世界の再生不良性貧血市場:企業プロファイル

  • Bayer AG
  • Novartis AG
  • Pfizer Inc.
  • Ligand Pharmceuticals Incorporated
  • Genezyme Corporation
  • Mylan N.V.
  • BIOGEN
  • Otsuka Pharmaceutical Co. Ltd.
  • REGEN BIOPHARMA INC.
  • BiolinRx、など

第14章 世界の再生不良性貧血市場:重要考察

第15章 世界の再生不良性貧血市場:DataM Intelligence

目次

Global Aplastic Anemia Market is segmented By Treatment Type (Blood transfusion, Drug therapy, Bone Marrow Transfusion), By Diseases Type (Acquired aplastic anemia, Inherited bone marrow failure syndromes), By Route of Administration (Intravenous, Oral), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Aplastic Anemia Market is expected to grow at a CAGR during the forecasting period (2020-2027).

Aplastic Anemia is a condition that happens when the body stops generating sufficient new blood cells. The condition leaves a person tired and more prone to uncontrolled bleeding and infections. Aplastic Anemia, a rare and serious condition, may develop at any age. It can happen suddenly, or slowly and worsen over time. It can be either moderate or severe. Medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant, may be included in aplastic anemia treatment.

Product: DataM Intelligence Analysis (2019)

Market Dynamics

The major factors propelling the growth of aplastic anemia market are the rising number of blood disorder cases worldwide and rising number of cancer patients globally. Moreover, the technological advancement in aplastic anemia and growing research & development activities in the pharmaceutical sector is further creating a lucrative opportunity for the market growth.

Rising number of blood disorder cases worldwide

Rising number of blood disorder cases across the world is the major factor stimulating the growth of the aplastic anemia market. For instance, as per Statista, Hemophilia A and B and von Willebrand disease are the most prevalent types of bleeding disorders. There were around 210,454 individuals worldwide who were diagnosed with haemophilia in 2018 and 78,500 who were diagnosed with von Willebrand disease. Also, in 2018, it was estimated that more than 13,600 individuals were diagnosed with haemophilia A in the US, while about 4,100 were diagnosed with haemophilia B. Thus, the rising number of blood disorders incidents worldwide and commendable application of aplastic anemia in its treatment is driving the growth of market over the forecast years.  

Higher treatment cost of aplastic anemia

Treatment costs are a major factor influencing the choice of therapy. Bone marrow transplantation costs are over USD 300,000. Thus, high treatment costs are likely to hamper the growth of the aplastic anemia market over the forecast period.

COVID-19 Impact Analysis

The outbreak of COVID-19 has positive impact on the growth of the aplastic anemia market globally. Since, people receiving active treatment for aplastic anaemia immunosuppression involves a higher risk of infection and complications; however, may be beneficial if immunosuppression reduces the late destruction of hyperinflammatory tissue. Therefore, the COVID-19 pandemic has driven the market value of the aplastic anemia market in 2020.

Market Segment Analysis

Based on the treatment type, the aplastic anemia market has been classified into bone marrow transfusion/stem cell therapy, blood transfusion and drug therapy.

Bone marrow transfusion/ stem cell therapy segment is projected to be the dominated segment in the market during the forecast period.

For decades, hematopoietic stem cell transplantation, either unpatched or genetically altered to correct genetic disorders, has been used to treat blood and cardiovascular cells disorders. Also, it is an efficient option for blood disorders with a success rate of over 80% as per research presented by american academy of orthopaedic surgeons. Thus, rising blood disorders worldwide and efficient usage of stem cell in treatment of blood disorder is expected to drive the usage of bone marrow transfusion. 

Aplastic Anemia is segmented on the basis of distribution channel, which includes retail pharmacies, hospitals pharmacies and online pharmacies.

Hospitals pharmacies is expected to dominate the aplastic anemia market.

Hospitals pharmacies held the dominant position in the global market during the forecast period. Hospital pharmacy is a specialised area of pharmacy that is integrated into the care of the medical centre. These include centres such as a hospital, an outpatient clinic, a drug-dependent facility, a poison control centre, a drug information centre at a residential care facility. The hospitals pharmacies is expected to gain a potential growth in the forthcoming period due to the growing geriatric population and rising number of chronic diseases. Moreover, the online pharmacies is expected to project a considerable CAGR during the forecast period. Rising e-commerce sector is expected to propel the segment growth in the near future.

Product: DataM Intelligence Analysis (2019)

Additionally, aplastic anemia is segmented on the basis of disease type, which includes acquired aplastic anemia and inherited bone marrow failure syndromes. Similarly, the route of administration includes intravenous and oral.

Geographical Analysis

Based on geography, the study analyzes the aplastic anemia market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

North America is expected to dominate the global aplastic anemia market.

North America is held a dominant position in the global aplastic anemia market in 2019. In North America, the U.S. is expected to represent considerable growth during the forecast period. In the U.S., the aplastic anemia is expected to have potential growth owing to the high prevalence rate of blood disorder. Moreover, Latin America is expected to represent significant growth in terms of value during the forecast period. The rise in prevalence rate of aplastic anemia and bone marrow disorder is expected to propel the market growth across the region. Aplastic Anemia market for Asia Pacific is expected to observe rapid growth over the forecast period, backed by the growth of the pharmaceutical industry & technological advancement in the India and China. Moreover, the increasing population and increasing prevalence of chronic diseases, is expected to augment the growth the Asia Pacific aplastic anemia market.

Competitive Landscape

The key aplastic anemia players which are contributing to the growth of the global market include Bayer AG, Novartis AG, Pfizer Inc., Ligand Pharmceuticals Incorporated, Genezyme Corporation, Mylan N.V., BIOGEN, OTSUKA PHARMACEUTICAL CO. LTD., REGEN BIOPHARMA INC., and BiolinRx, among others. The major players are adopting new product launch and expansion strategies for global growth in the aplastic anemia market.  

Stem cell therapy (Pfizer):

Pfizer Regenerative Medicine focused on the use of stem cells to develop future treatments for the prevention of disability, organ failure and treatment of degenerative diseases. Additionally, company provides blood transfusion and other drug therapies for aplastic anemia.

Product Portfolio: The Company's portfolio comprises essential, drugs & medicines along with different therapies such as blood marrow transfusion among others.

Why Purchase the Report?

Visualize the Aplastic Anemia market segmentation composition by treatment type, distribution channel, disease type and route of administration, and region, highlighting the critical commercial assets and players.

Identify commercial opportunities in the Aplastic Anemia market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of Aplastic Anemia market - level 3 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global Aplastic Anemia market report would provide access to an approx. 60 market data table, 61 figures and 254 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

Table of Contents

Global Aplastic Anemia Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Global Aplastic Anemia Market - Market Definition and Overview

Global Aplastic Anemia Market - Executive Summary

Market Snippet by Treatment Type

Market Snippet by Disease Type

Market Snippet by Route of Administration

Market Snippet by Distribution Channel

Market Snippet by Region

Global Aplastic Anemia Market - Market Dynamics

Market Impacting Factors

Drivers

Rising number of blood disorder cases across the world

Rising number of cancer patients

Restraint

High cost of treatment

Impact Analysis

Global Aplastic Anemia Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Value Chain Analysis

PEST Analysis

Pricing Analysis

Regulatory Analysis

Reimbursement Analysis

Unmet Needs

Patent Trends

Global Aplastic Anemia Market - COVID-19 Analysis

Analysis of Covid-19 on the Market

Before COVID-19 Market Scenario

Present COVID-19 Market Scenario

After COVID-19 or Future Scenario

Pricing Dynamics Amid Covid-19

Demand-Supply Spectrum

Government Initiatives Related to the Market During Pandemic

Manufacturers Strategic Initiatives

Conclusion 

Global Aplastic Anemia Market - By Treatment Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment

Market Attractiveness Index, By Treatment Type Segment

Blood transfusion

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Drug therapy

Bone Marrow Transfusion

Global Aplastic Anemia Market - By Diseases Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment

Market Attractiveness Index, By Diseases Type Segment

Acquired aplastic anemia

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Inherited bone marrow failure syndromes

Global Aplastic Anemia Market - By Route of Administration

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment

Market Attractiveness Index, By Route of Administration Segment

Intravenous

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Oral

Global Aplastic Anemia Market - By Distribution Channel

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

Market Attractiveness Index, By Distribution Channel Segment

Retail pharmacies

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%)

Hospital pharmacies

Online pharmacies

Global Aplastic Anemia Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Italy

Spain

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Global Aplastic Anemia Market - Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Global Aplastic Anemia Market- Company Profiles

Bayer AG*

Company Overview

Product Portfolio and Description

Key Highlights

Financial Overview

Novartis AG

Pfizer Inc.

Ligand Pharmceuticals Incorporated

Genezyme Corporation

Mylan N.V.

BIOGEN

Otsuka Pharmaceutical Co. Ltd.

REGEN BIOPHARMA INC.

BiolinRx (*LIST NOT EXHAUSTIVE)

Global Aplastic Anemia Market - Premium Insights

Global Aplastic Anemia Market - DataM Intelligence Analysis

Appendix

About Us and Services

Contact Us